GeoVax Expands Scientific Advisory Board with Global Vaccine and Immunology Experts

GeoVax Labs, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancers, announced an update to its Scientific Advisory Board, welcoming internationally recognized experts whose work spans vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised-host medicine. This strategic expansion is designed to support GeoVax's current and future development efforts with MVA and its multi-antigen MVA vector platform for vaccines targeting biothreat pathogens and vulnerable or currently underserved populations such as those from low- and middle-income countries, and immunocompromised patients.

Newly appointed members include Dr. Alessandro Sette of the La Jolla Institute for Immunology, an authority in T-cell epitope mapping who leads the NIH Immune Epitope Database (IEDB) and is recognized for defining T-cell immunity across SARS-CoV-2, Mpox, and Ebola. Prof. Lance Turtle of the University of Liverpool specializes in viral pathogenesis and post-infection immune recovery, providing translational insights into long-term immunity and emerging pathogen preparedness. Prof. Thushan I. de Silva of the University of Sheffield is an expert in human viral immunology, vaccine responses, and global immunosurveillance, leading studies across Europe, Asia, and Africa evaluating population-level vaccine immunity and viral evolution.

Dr. Joshua A. Hill of the University of Washington School of Medicine focuses on vaccine response in immunocompromised and transplant patients, aligning with GeoVax's emphasis on protecting high-risk, underserved populations. These experts join Prof. Teresa Lambe of the University of Oxford, whose appointment was previously announced. David Dodd, GeoVax Chairman & CEO, stated that assembling this exceptional team strengthens GeoVax's position at the forefront of vaccine innovation, with their combined experience aligning with the mission to deliver durable, broad-spectrum protection to both global and immunocompromised populations.

Dr. Kelly McKee, Chief Medical Officer, added that the addition ensures clinical strategy is guided by cutting-edge immunology insight and global research expertise, with collaboration instrumental as GeoVax advances vaccines and immunotherapies designed to protect vulnerable populations, particularly in low and middle income countries and immunocompromised patients underserved by traditional approaches. Dr. Mark Newman, Chief Scientific Officer, noted that the expanded SAB strengthens multiple aspects of the R&D platform, ensuring vaccine and immunotherapy candidates deliver real-world impact with input from respected scientific leaders.

The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster in patients with chronic lymphocytic leukemia, and a more robust booster among healthy patients who previously received mRNA vaccines. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. For more information, visit https://www.geovax.com.